Pelthos Therapeutics Inc. Files 8-K on Executive Changes

Ticker: PTHS · Form: 8-K · Filed: 2025-12-23T00:00:00.000Z

Sentiment: neutral

Topics: executive-changes, board-composition, governance

TL;DR

Pelthos Inc. 8-K filed 12/23/25: Exec changes, director elections, officer appointments, and compensation details.

AI Summary

Pelthos Therapeutics Inc. filed an 8-K on December 23, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also covers other events and financial statements/exhibits.

Why It Matters

This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational execution.

Risk Assessment

Risk Level: medium — Changes in executive and director positions can signal internal shifts or strategic realignments that may carry inherent business risks.

Key Players & Entities

FAQ

Who specifically departed from their roles at Pelthos Therapeutics Inc.?

The filing indicates the 'Departure of Directors or Certain Officers' as an item reported, but does not name the individuals in the provided text.

Were any new directors or officers appointed?

Yes, the filing explicitly lists 'Election of Directors' and 'Appointment of Certain Officers' as reported items.

What is the nature of the 'Compensatory Arrangements' mentioned?

The filing states 'Compensatory Arrangements of Certain Officers' are being reported, but the specific details of these arrangements are not provided in the excerpt.

What other events are being reported in this 8-K?

The filing also covers 'Other Events' in addition to the executive and director changes.

When was Pelthos Therapeutics Inc. incorporated?

Pelthos Therapeutics Inc. was incorporated in Nevada.

From the Filing

0001753926-25-001964.txt : 20251223 0001753926-25-001964.hdr.sgml : 20251223 20251223173032 ACCESSION NUMBER: 0001753926-25-001964 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20251223 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251223 DATE AS OF CHANGE: 20251223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pelthos Therapeutics Inc. CENTRAL INDEX KEY: 0001919246 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 863335449 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41964 FILM NUMBER: 251601878 BUSINESS ADDRESS: STREET 1: 4020 STIRRUP CREEK DRIVE STREET 2: SUITE 110 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-908-2422 MAIL ADDRESS: STREET 1: 4020 STIRRUP CREEK DRIVE STREET 2: SUITE 110 CITY: DURHAM STATE: NC ZIP: 27703 FORMER COMPANY: FORMER CONFORMED NAME: Channel Therapeutics Corp DATE OF NAME CHANGE: 20241118 FORMER COMPANY: FORMER CONFORMED NAME: Chromocell Therapeutics Corp DATE OF NAME CHANGE: 20220323 8-K 1 g085052_8k.htm 8-K false 0001919246 0001919246 2025-12-23 2025-12-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): December 23, 2025   Pelthos Therapeutics Inc. (Exact name of registrant as specified in its charter)   Nevada   001-41964   86-3335449 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   4020 Stirrup Creek Drive , Suite 110 Durham , NC   27703 (Address of registrant’s principal executive office)   (Zip code)   Registrant’s telephone number, including area code: (919) 908-2400       (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   PTHS   The NYSE American LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐           Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer

View on Read The Filing